ResMed (RMD) Competitors

ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.2%. Encompass Health pays an annual dividend of $0.76 per share and has a dividend yield of 0.7%. ResMed pays out 23.1% of its earnings in the form of a dividend. Encompass Health pays out 12.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. ResMed has increased its dividend for 13 consecutive years and Encompass Health has increased its dividend for 2 consecutive years. ResMed is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

ResMed has a net margin of 27.44% compared to Encompass Health's net margin of 10.04%. ResMed's return on equity of 25.35% beat Encompass Health's return on equity.

55.0% of ResMed shares are owned by institutional investors. Comparatively, 97.3% of Encompass Health shares are owned by institutional investors. 0.7% of ResMed shares are owned by company insiders. Comparatively, 1.8% of Encompass Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

ResMed has higher earnings, but lower revenue than Encompass Health. Encompass Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

ResMed has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Encompass Health has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

ResMed currently has a consensus target price of $250.00, indicating a potential upside of 24.57%. Encompass Health has a consensus target price of $143.86, indicating a potential upside of 27.06%. Given Encompass Health's stronger consensus rating and higher possible upside, analysts clearly believe Encompass Health is more favorable than ResMed.

In the previous week, ResMed had 15 more articles in the media than Encompass Health. MarketBeat recorded 18 mentions for ResMed and 3 mentions for Encompass Health. Encompass Health's average media sentiment score of 1.18 beat ResMed's score of 0.70 indicating that Encompass Health is being referred to more favorably in the news media.

ResMed has higher revenue and earnings than Hims & Hers Health. Hims & Hers Health is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

In the previous week, ResMed had 10 more articles in the media than Hims & Hers Health. MarketBeat recorded 18 mentions for ResMed and 8 mentions for Hims & Hers Health. Hims & Hers Health's average media sentiment score of 0.83 beat ResMed's score of 0.70 indicating that Hims & Hers Health is being referred to more favorably in the news media.

ResMed has a net margin of 27.44% compared to Hims & Hers Health's net margin of -0.56%. ResMed's return on equity of 25.35% beat Hims & Hers Health's return on equity.

55.0% of ResMed shares are owned by institutional investors. Comparatively, 63.5% of Hims & Hers Health shares are owned by institutional investors. 0.7% of ResMed shares are owned by insiders. Comparatively, 11.8% of Hims & Hers Health shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

ResMed currently has a consensus price target of $250.00, suggesting a potential upside of 24.57%. Hims & Hers Health has a consensus price target of $30.70, suggesting a potential downside of 5.93%. Given ResMed's stronger consensus rating and higher possible upside, equities analysts clearly believe ResMed is more favorable than Hims & Hers Health.

ResMed has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Hims & Hers Health has a beta of 2.35, indicating that its share price is 135% more volatile than the broader market.

ResMed pays an annual dividend of $2.40 per share and has a dividend yield of 1.2%. Medtronic pays an annual dividend of $2.88 per share and has a dividend yield of 3.4%. ResMed pays out 23.1% of its earnings in the form of a dividend. Medtronic pays out 77.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ResMed has increased its dividend for 13 consecutive years and Medtronic has increased its dividend for 49 consecutive years. Medtronic is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

In the previous week, Medtronic had 8 more articles in the media than ResMed. MarketBeat recorded 26 mentions for Medtronic and 18 mentions for ResMed. Medtronic's average media sentiment score of 1.02 beat ResMed's score of 0.70 indicating that Medtronic is being referred to more favorably in the news media.

ResMed has a beta of 0.78, meaning that its share price is 22% less volatile than the broader market. Comparatively, Medtronic has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

Medtronic has higher revenue and earnings than ResMed. ResMed is trading at a lower price-to-earnings ratio than Medtronic, indicating that it is currently the more affordable of the two stocks.

55.0% of ResMed shares are held by institutional investors. Comparatively, 82.1% of Medtronic shares are held by institutional investors. 0.7% of ResMed shares are held by insiders. Comparatively, 0.3% of Medtronic shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ResMed has a net margin of 27.44% compared to Medtronic's net margin of 13.20%. ResMed's return on equity of 25.35% beat Medtronic's return on equity.

ResMed currently has a consensus target price of $250.00, indicating a potential upside of 24.57%. Medtronic has a consensus target price of $98.21, indicating a potential upside of 17.33%. Given ResMed's higher possible upside, analysts plainly believe ResMed is more favorable than Medtronic.

In the previous week, Boston Scientific had 16 more articles in the media than ResMed. MarketBeat recorded 34 mentions for Boston Scientific and 18 mentions for ResMed. Boston Scientific's average media sentiment score of 0.77 beat ResMed's score of 0.70 indicating that Boston Scientific is being referred to more favorably in the media.

Boston Scientific has a beta of 0.58, indicating that its stock price is 42% less volatile than the broader market. Comparatively, ResMed has a beta of 0.78, indicating that its stock price is 22% less volatile than the broader market.

Boston Scientific has higher revenue and earnings than ResMed. Boston Scientific is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Boston Scientific presently has a consensus price target of $79.84, indicating a potential upside of 80.73%. ResMed has a consensus price target of $250.00, indicating a potential upside of 24.57%. Given Boston Scientific's stronger consensus rating and higher probable upside, research analysts plainly believe Boston Scientific is more favorable than ResMed.

ResMed has a net margin of 27.44% compared to Boston Scientific's net margin of 17.29%. ResMed's return on equity of 25.35% beat Boston Scientific's return on equity.

89.1% of Boston Scientific shares are owned by institutional investors. Comparatively, 55.0% of ResMed shares are owned by institutional investors. 0.3% of Boston Scientific shares are owned by insiders. Comparatively, 0.7% of ResMed shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.